Synermore Biologics

Synermore Biologics is a biopharmaceutical company focused on the research, development, production, and sales of monoclonal antibody drugs and biosimilars. The company operates in the fields of oncology, infectious diseases, and immune disorders. It has established a complete industrial chain for humanized monoclonal antibody drugs, from design to quality assurance.

The original company was founded in Taipei in 2013 by Eric Tsao. Tsao, who holds a Ph.D. in Biochemical Engineering, founded the company to leverage the growing biological product development in Greater China, establishing an R&D headquarters in Taipei and other assets in mainland China. In 2016, Synermore Biologics (Suzhou) Co., Ltd. was established, backed by an investment from SINOVAC. This entity has two 2000L production lines that became operational in December 2017.

The company's business model involves developing both innovative products and biosimilars internally. Some of these products are intended to be licensed out to larger pharmaceutical and biotech companies for Phase III trials and commercialization. The company's lead products include SYN004, an anti-EGFR monoclonal antibody for cancer treatment which is in Phase I trials, and SYN023, an antibody cocktail for rabies post-exposure prophylaxis. In May 2022, an FDA application was submitted in China for Zamerovimab and Mazorelvimab Injection.

Keywords: monoclonal antibodies, biosimilars, biologics development, oncology therapeutics, infectious disease treatment, autoimmune disease therapy, biopharmaceutical manufacturing, clinical stage pharma, antibody drug development, anti-EGFR antibody, rabies prophylaxis, drug research and development, biopharmaceutical sales